The Antisynthetase Syndrome: A Review
- 1Temple University Hospital, 3401 N. Broad St., Philadelphia, PA 19140, USA
- 2Jefferson-Einstein Medical Center, 5501 Old York Rd., Philadelphia, PA 19141, USA
Abstract
Anti-synthetase syndrome (ASyS) is a relatively new and distinct clinical entity within the group of idiopathic inflammatory myopathies (IIM) characterized by the presence of autoantibodies targeting aminoacyl-tRNA synthetase (ARS), a family of enzymes responsible for protein translation but now recognized to possess important extracellular immunomodulatory functions. Anti-Jo-1 remains the most prevalent and studied antibody, but there exist additional antibodies, including PL-7, PL-12, EJ, OJ, KS, Zo, and Ha. These antibodies define a clinically similar but heterogenic syndrome with a variable combination of inflammatory myopathy, interstitial lung disease (ILD), inflammatory arthritis, and Raynaud’s phenomenon. Only a minority of patients initially present with multiple symptoms, whereas isolated pulmonary, muscle, or articular manifestations frequently predominate. Interstitial lung disease remains the predominant cause of morbidity and mortality, but neuromuscular involvement is central to disease pathogenesis and patient disability. Current evidence supports a concept of pathogenesis in which genetically susceptible individuals develop aberrant innate and adaptive immune responses from tissue injury, leading to persistent inflammation and progressive fibrosis. Despite advances in understanding ASyS, the disease remains associated with significant morbidity and mortality, largely driven by ILD. This review summarizes current evidence regarding pathogenesis, genetic susceptibility, clinical manifestations, diagnostic evaluation, and evolving treatment strategies for ASyS.
Related
- Longitudinal Trajectories of Antisynthetase Syndrome-associated Interstitial Lung Disease
- Efgartigimod in the treatment of severe Guillain–Barre syndrome with overlapping autoantibody syndrome: a case report and updated clinical review
- Irritable bowel syndrome and restless legs syndrome: a narrative review of epidemiological and pathophysiological overlap
- Preventive strategies for postoperative hypocalcemia and hungry bone syndrome following parathyroidectomy: a systematic review and pairwise meta-analysis
- The DRESS/HLH Overlap Syndrome: A Systematic Review of Clinical Features, Triggers, and Outcomes
BibTeX
@article{zyskowski2026antisynthetase,
title = {{The Antisynthetase Syndrome: A Review}},
author = {Evan Zyskowski and Shahrzad Abdollahi and Lawrence H. Brent},
journal = {Journal of Clinical Medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15218308},
url = {https://www.mdpi.com/2077-0383/15/21/8308},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - The Antisynthetase Syndrome: A Review
AU - Evan Zyskowski
AU - Shahrzad Abdollahi
AU - Lawrence H. Brent
PY - 2026
DA - 2026/10/25
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15218308
UR - https://www.mdpi.com/2077-0383/15/21/8308
AB - Anti-synthetase syndrome (ASyS) is a relatively new and distinct clinical entity within the group of idiopathic inflammatory myopathies (IIM) characterized by the presence of autoantibodies targeting aminoacyl-tRNA synthetase (ARS), a family of enzymes responsible for protein translation but now recognized to possess important extracellular immunomodulatory functions. Anti-Jo-1 remains the most prevalent and studied antibody, but there exist additional antibodies, including PL-7, PL-12, EJ, OJ, KS, Zo, and Ha. These antibodies define a clinically similar but heterogenic syndrome with a variable combination of inflammatory myopathy, interstitial lung disease (ILD), inflammatory arthritis, and Raynaud’s phenomenon. Only a minority of patients initially present with multiple symptoms, whereas isolated pulmonary, muscle, or articular manifestations frequently predominate. Interstitial lung disease remains the predominant cause of morbidity and mortality, but neuromuscular involvement is central to disease pathogenesis and patient disability. Current evidence supports a concept of pathogenesis in which genetically susceptible individuals develop aberrant innate and adaptive immune responses from tissue injury, leading to persistent inflammation and progressive fibrosis. Despite advances in understanding ASyS, the disease remains associated with significant morbidity and mortality, largely driven by ILD. This review summarizes current evidence regarding pathogenesis, genetic susceptibility, clinical manifestations, diagnostic evaluation, and evolving treatment strategies for ASyS.
SN - 2077-0383
ER -